Chest. 1990 Oct;98(4):907-10.
From June 1988 to February 1989, we enrolled 36 patients with human immunodeficiency virus into a randomized double-blind placebo-controlled trial assessing the efficacy and toxicity of aerosolized pentamidine (AP) as secondary prophylaxis for Pneumocystis carinii pneumonia. Each patient underwent spirometric evaluations before and after aerosolized treatment. There was no significant difference in the results of baseline pulmonary function tests between the two groups. Eleven patients (65 percent) in the AP group developed cough but only four demonstrated significant reduction in the forced expiratory flow rates after AP; four patients (21 percent) in the placebo group developed cough, but no significant change in the expiratory flow rates was noted. All bronchospastic episodes were self-limited and symptomatically responded to remedial inhaled albuterol (salbutamol) treatment. We conclude that AP treatment is frequently associated with coughing attacks (65 percent), but the actual incidence of bronchospasm on spirometry is much lower (24 percent) and is generally quite mild.
1988年6月至1989年2月，我们将36例人类免疫缺陷病毒感染者纳入一项随机双盲安慰剂对照试验，评估雾化喷他脒（AP）作为卡氏肺孢子虫肺炎二线预防措施的疗效和毒性。每位患者在雾化治疗前后均接受了肺功能测定评估。两组的基线肺功能测试结果无显著差异。AP组有11例患者（65%）出现咳嗽，但只有4例在接受AP治疗后用力呼气流量显著降低；安慰剂组有4例患者（21%）出现咳嗽，但呼气流量无显著变化。所有支气管痉挛发作均为自限性，对症吸入沙丁胺醇治疗后症状缓解。我们得出结论，AP治疗常伴有咳嗽发作（65%），但肺功能测定显示支气管痉挛的实际发生率要低得多（24%），且通常较为轻微。
